Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Research Council grant · Running

ACBP-DBI - Cancer Cancer immunosurveillance-stimulatory effects of ACBP/DBI neutralization

Coordinator
Universite Paris Cite, France
Runs
1 April 2026 to 30 September 2027
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101233365

What the project is doing

In the project's own words, from its summary on CORDIS.

Acyl CoA binding protien (ACBP, encoded by diazepam binding inhibitor, DBI) is a novel glucocorticoid-induced tissue hormone that contributes to tissue aging. In still health individuals, the plasma concentrations of ACBP/DBI protein increase before cancer diagnosis. ACBP/DBI mediates immunosuppressive effects, meaning that its neutralization improves cancer immunosurveillance. Therefore, ACBP/DBI might be considered as an immune checkpoint.

Thus far, we have demonstrated the immunostimulatory and cancer immunotherapeutic effects of ACBP/DBI inhibition by the inducible knockout of the Dbi gene or by means of a tool antibody recognizing mouse (but not human) ACBP/DBI protein. Here, we propose the validation of an interspecies cross-reactive monoclonal antibody (mAb) recognizing an epitope that is shared among human and mouse ACBP/DBI. We plan to test this new (unpublished) antibody in three experimental settings: (i) the neutralization of human recombinant ACBP/DBI protein, abolishing its capacity to elict chloride fluxes via the GABAA receptor expressed by human cells; (ii) the reversal of the immunosuppressive effects of human recombinant ACBP/DBI protein or glucocorticoids (which transcriptionally induce ACBP/DBI) on primary human peripheral blood mononuclear cells; and (iii) the improvement of immunosurveillance and the reversal of immunosuppression by glucocorticoids in mouse models of non-small cell lung cancer, fibrosarcoma and breast cancer.

Altogether, these results should allow to file a composition-of-matter patent describing a therapeutically useful anti-ACBP/DBI mAb. Moreover, such data will increase the interest of potential investors in a yet-to-be-financed biotech company developing therapeutic anti-ACBP/DBI mAbs for the treatment of cancer and other age-related diseases.

Topics

Who is involved

OrganisationCityCountryRole
Universite Paris CiteParisFranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI